NEULANDLAB

Neuland Laboratories Limited

Neuland Laboratories Limited (NEULANDLAB) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

neulandlabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹19675.00
Market cap
25,382 Cr
Stock P/E
51.0
P/B
13.54
Dividend yield
0.1%
ROE (FY26)
19.4%
ROCE (FY26)
24.8%
Operating margin (FY26)
23.9%
Debt / equity (FY26)
0.10
OCF / EBITDA (FY26)
60.3%
OCF / EBITDA (3Y)
68.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Neuland Laboratories makes active pharmaceutical ingredients (APIs) for pharmaceutical customers, both as generic APIs and as custom development and manufacturing (CDMO) work for innovator drug companies.

Company snapshot

25thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 18.0% — the business keeps a healthy share of every rupee it earns.
3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales418 Cr393 Cr385 Cr440 Cr311 Cr398 Cr328 Cr293 Cr514 Cr440 Cr776 Cr642 Cr
Operating expenses (approx.)280 Cr272 Cr278 Cr316 Cr249 Cr311 Cr277 Cr258 Cr359 Cr363 Cr469 Cr419 Cr
EBITDA137 Cr121 Cr107 Cr123 Cr62 Cr87 Cr51 Cr34 Cr156 Cr77 Cr307 Cr223 Cr
OPM %32.9%30.9%27.8%28.1%20.0%21.8%15.6%11.8%30.2%17.5%39.6%34.7%
Other income3 Cr2 Cr5 Cr5 Cr4 Cr4 Cr7 Cr8 Cr2 Cr8 Cr12 Cr8 Cr
Interest4 Cr4 Cr4 Cr3 Cr1 Cr2 Cr2 Cr5 Cr5 Cr7 Cr7 Cr7 Cr
Depreciation15 Cr15 Cr16 Cr16 Cr16 Cr16 Cr17 Cr20 Cr23 Cr24 Cr25 Cr27 Cr
Profit before tax122 Cr104 Cr92 Cr130 Cr49 Cr128 Cr39 Cr18 Cr129 Cr54 Cr287 Cr198 Cr
Tax %26.6%22.1%26.7%24.6%33.5%20.5%29.2%20.9%25.2%25.5%26.0%25.4%
Net profit89 Cr81 Cr68 Cr98 Cr33 Cr102 Cr28 Cr14 Cr97 Cr41 Cr213 Cr148 Cr
EPS (₹)₹69.56₹63.44₹52.66₹76.28₹25.60₹79.18₹21.67₹10.83₹75.49₹31.62₹165.76₹115.10

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales588 Cr529 Cr667 Cr763 Cr937 Cr951 Cr1,191 Cr1,559 Cr1,477 Cr2,023 CrSign in free for the trailing twelve months
Operating expenses (approx.)481 Cr479 Cr608 Cr661 Cr790 Cr808 Cr919 Cr1,096 Cr1,154 Cr1,448 CrSign in free for the trailing twelve months
EBITDA106 Cr50 Cr58 Cr102 Cr147 Cr143 Cr272 Cr463 Cr323 Cr574 CrSign in free for the trailing twelve months
OPM %18.1%9.5%8.8%13.4%15.7%15.0%22.8%29.7%21.9%28.4%Sign in free for the trailing twelve months
Other income1 Cr5 Cr3 Cr4 Cr16 Cr2 Cr10 Cr13 Cr21 Cr30 CrSign in free for the trailing twelve months
Interest21 Cr19 Cr16 Cr22 Cr18 Cr13 Cr13 Cr14 Cr8 Cr24 CrSign in free for the trailing twelve months
Depreciation19 Cr22 Cr26 Cr31 Cr40 Cr49 Cr53 Cr60 Cr66 Cr92 CrSign in free for the trailing twelve months
Profit before tax67 Cr14 Cr20 Cr53 Cr105 Cr82 Cr216 Cr401 Cr346 Cr489 CrSign in free for the trailing twelve months
Tax %30.2%13.4%19.2%69.4%23.5%22.3%24.2%25.2%24.9%25.6%Sign in free for the trailing twelve months
Net profit47 Cr12 Cr16 Cr16 Cr81 Cr64 Cr164 Cr300 Cr260 Cr364 CrSign in free for the trailing twelve months
EPS (₹)₹42.01₹10.81₹13.06₹12.63₹62.85₹49.74₹127.45₹233.89₹202.74₹283.71Sign in free for the trailing twelve months
Dividend payout %————3.2%6.0%3.9%4.3%6.9%4.2%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital9 Cr9 Cr13 Cr13 Cr13 Cr13 Cr13 Cr13 Cr13 Cr13 Cr
Reserves537 Cr549 Cr686 Cr697 Cr774 Cr828 Cr981 Cr1,270 Cr1,512 Cr1,862 Cr
Borrowings181 Cr303 Cr210 Cr246 Cr145 Cr231 Cr122 Cr83 Cr136 Cr197 Cr
Other liabilities159 Cr211 Cr221 Cr275 Cr393 Cr312 Cr464 Cr467 Cr519 Cr859 Cr
Total liabilities886 Cr1,071 Cr1,130 Cr1,231 Cr1,325 Cr1,383 Cr1,580 Cr1,833 Cr2,180 Cr2,930 Cr
Fixed assets (net)155 Cr164 Cr230 Cr337 Cr402 Cr457 Cr457 Cr523 Cr674 Cr892 Cr
CWIP20 Cr126 Cr104 Cr24 Cr17 Cr20 Cr41 Cr46 Cr45 Cr209 Cr
Investments8 Cr8 Cr38 Cr38 Cr25 Cr24 Cr20 Cr20 Cr109 Cr2 Cr
Inventories135 Cr175 Cr193 Cr220 Cr248 Cr265 Cr279 Cr350 Cr386 Cr510 Cr
Trade receivables181 Cr194 Cr164 Cr190 Cr218 Cr234 Cr362 Cr374 Cr316 Cr541 Cr
Cash & bank3 Cr3 Cr8 Cr11 Cr2 Cr5 Cr45 Cr88 Cr132 Cr77 Cr
Other assets383 Cr401 Cr393 Cr411 Cr413 Cr378 Cr375 Cr432 Cr519 Cr698 Cr
Total assets886 Cr1,071 Cr1,130 Cr1,231 Cr1,325 Cr1,383 Cr1,580 Cr1,833 Cr2,180 Cr2,930 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity39 Cr11 Cr70 Cr57 Cr189 Cr59 Cr237 Cr261 Cr317 Cr347 Cr
Cash from investing-42 Cr-116 Cr-77 Cr-49 Cr-84 Cr-94 Cr-61 Cr-150 Cr-298 Cr-424 Cr
Cash from financing-0.09 Cr105 Cr12 Cr-5 Cr-114 Cr38 Cr-136 Cr-69 Cr25 Cr21 Cr
Net cash flow-4 Cr-0.17 Cr5 Cr3 Cr-9 Cr3 Cr40 Cr42 Cr44 Cr-55 Cr
Free cash flow (OCF − Capex)-2 Cr-122 Cr7 Cr9 Cr84 Cr-37 Cr171 Cr118 Cr111 Cr-50 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %12.2%3.8%4.0%7.8%13.2%8.9%20.5%30.4%21.4%24.8%
ROE %8.6%2.2%2.4%2.3%10.3%7.6%16.4%23.4%17.1%19.4%
Debtor days11213390918590111877897
Inventory days182227195205205221208202244227
Days payable11616112310812693128111160120
Cash conversion cycle178199161188164217191179162204
OCF / EBITDA %36.4%22.3%119.8%56.3%129.0%41.1%87.3%56.5%98.2%60.3%
OCF / EBITDA % (3 years)——55.7%65.7%103.1%78.0%86.4%63.5%77.1%68.0%
Debt / equity0.330.540.300.350.180.270.120.060.090.10
Current ratio1.311.221.391.441.491.601.732.152.452.09
Net debt / EBITDA1.675.943.462.300.971.580.28-0.010.010.21